Drug intelligence / Profile preview

Coca-Cola

Development stage: Unknown
Lead developer: The Coca-Cola Company
Modality: Small Molecules
Administration: Oral

Overview

Coca-Cola is a popular carbonated soft drink invented in 1886 by pharmacist John Stith Pemberton. Originally marketed as a patent medicine, its early formulation contained extracts from coca leaves (which provided cocaine) and kola nuts (a source of caffeine). While cocaine was removed from the formula around 1903, the drink continues to contain caffeine and natural flavors derived from coca leaves (after cocaine extraction). It is primarily consumed as a beverage, though it has been anecdotally used for ailments like nausea and gastric phytobezoars.

Brand names: Coca-ColaCoke

Targets

ADOR (Adenosine receptors)

Beyond the preview

Go deeper on Coca-Cola.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coca-Cola.

Explore the full profile